0001725160-24-000004.txt : 20240103 0001725160-24-000004.hdr.sgml : 20240103 20240103202108 ACCESSION NUMBER: 0001725160-24-000004 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240102 FILED AS OF DATE: 20240103 DATE AS OF CHANGE: 20240103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lackner Mark CENTRAL INDEX KEY: 0001777413 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39263 FILM NUMBER: 24509407 MAIL ADDRESS: STREET 1: C/O IDEAYA BIOSCIENCES, INC. STREET 2: 7000 SHORELINE COURT, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Zentalis Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001725160 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 823607803 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1359 BROADWAY, SUITE 801 CITY: NEW YORK STATE: NY ZIP: 10018 BUSINESS PHONE: (212) 433-3791 MAIL ADDRESS: STREET 1: 1359 BROADWAY, SUITE 801 CITY: NEW YORK STATE: NY ZIP: 10018 FORMER COMPANY: FORMER CONFORMED NAME: Zentalis Pharmaceuticals, LLC DATE OF NAME CHANGE: 20200107 FORMER COMPANY: FORMER CONFORMED NAME: Zeno Pharma, LLC DATE OF NAME CHANGE: 20171212 4 1 wk-form4_1704331256.xml FORM 4 X0508 4 2024-01-02 0 0001725160 Zentalis Pharmaceuticals, Inc. ZNTL 0001777413 Lackner Mark C/O ZENTALIS PHARMACEUTICALS, INC. 1359 BROADWAY, SUITE 801 NEW YORK NY 10018 0 1 0 0 Chief Scientific Officer 0 Common Stock 2024-01-02 4 A 0 40000 0 A 56313 D Stock Option (Right to Buy) 15.99 2024-01-02 4 A 0 60000 0 A 2034-01-02 Common Stock 60000 60000 D Represents restricted stock units ("RSUs") granted to the Reporting Person in connection with Reporting Person's previously disclosed promotion to Chief Scientific Officer, which became effective December 31, 2023. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in substantially equal annual installments on the first, second, third and fourth anniversaries of the vesting commencement date of December 31, 2023, subject to the Reporting Person's continuing service with the Issuer. The options were granted to the Reporting Person in connection with Reporting Person's previously disclosed promotion to Chief Scientific Officer, which became effective December 31, 2023. The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. /s/ Andrea Paul, attorney-in-fact for Mark Lackner 2024-01-03